Imaging of meningiomas using phenylbenzothiazole, stilbene, or biphenylalkyne derivatives
Methods for detecting or ruling out a meningioma in a patient using a phenylbenzothiazole derivative or a stilbene derivative or a biphenylalkyne derivative, and a medical imaging technique such as positron emission tomography/computed tomography are disclosed. In one version of the method, the phenylbenzothiazole derivative is a compound of formula (V):
1. A method for detecting or ruling out a meningioma in a patient, the method comprising:
(a) administering to a patient a detectable amount of a compound of formula (I):
wherein the compound is targeted to any meningiomas in the patient; and
(b) acquiring an image to detect the presence or absence of any meningiomas in the patient,
wherein R 1 is OH, R 2 is H, and R 3 is NH 11 CH 3 , and
wherein the meningiomas do not contain amyloid.
2. The method of claim 1 wherein: step (b) comprises acquiring the image using an imaging method selected from positron emission tomography imaging, positron emission tomography with computed tomography imaging, positron emission tomography with magnetic resonance imaging, or any combination thereof.
3. The method of claim 1 wherein:
step (b) comprises acquiring the image using positron emission tomography imaging.
4. The method of claim 1 wherein:
step (b) comprises acquiring the image using positron emission tomography with computed tomography imaging.
5. The method of claim 1 wherein:
step (b) comprises acquiring the image using positron emission tomography with magnetic resonance imaging.
6. The method of claim 1 wherein:
the presence of any meningiomas in the patient is indicated by an image in which meningiomas showed activity of the compound greater than normal adjacent tissues imaged.
7. The method of claim 1 wherein:
the presence of any meningiomas in the patient is indicated by a brain image in which meningiomas showed activity of the compound greater than any other intracranial tumors imaged.
8. The method of claim 1 wherein:
the presence of any meningiomas in the patient is indicated by a brain image in which meningiomas showed activity of the compound greater than any metastases, pituitary macroadenomas, schwannomas, or ependymomas imaged.
9. The method of claim 1 wherein:
the presence of any meningiomas in the patient is indicated by an image in which meningiomas showed activity of the compound greater than any metastases imaged.
10. A method for detecting or ruling out a meningioma in a patient, the method comprising:
(a) administering to a patient a detectable amount of a compound of formula (V):
wherein the compound is targeted to any meningiomas in the patient; and
(b) acquiring an image using positron emission tomography imaging to detect the presence or absence of any meningiomas in the patient,
wherein the meningiomas do not contain amyloid.
11. The method of claim 10 wherein:
the presence of any meningiomas in the patient is indicated by an image in which meningiomas showed activity of the compound greater than normal adjacent tissues imaged.
12. The method of claim 10 wherein:
the presence of any meningiomas in the patient is indicated by a brain image in which meningiomas showed activity of the compound greater than any other intracranial tumors imaged.
13. The method of claim 10 wherein:
the presence of any meningiomas in the patient is indicated by a brain image in which meningiomas showed activity of the compound greater than any metastases, pituitary macroadenomas, schwannomas, or ependymomas imaged.
14. The method of claim 10 wherein:
the presence of any meningiomas in the patient is indicated by an image in which meningiomas showed activity of the compound greater than any metastases imaged.